Invesco’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-63,542
| Closed | -$3.02M | – | 3747 |
|
|
2025
Q3 | $3.02M | Sell |
63,542
-103,763
| -62% | -$5.02M | ﹤0.01% | 2451 |
|
|
2025
Q2 | $8.93M | Buy |
167,305
+50,184
| +43% | +$2.28M | ﹤0.01% | 1849 |
|
|
2025
Q1 | $4.74M | Buy |
117,121
+18,658
| +19% | +$791K | ﹤0.01% | 2184 |
|
|
2024
Q4 | $2.74M | Buy |
98,463
+21,086
| +27% | +$639K | ﹤0.01% | 2500 |
|
|
2024
Q3 | $2.22M | Sell |
77,377
-38,411
| -33% | -$1M | ﹤0.01% | 2561 |
|
|
2024
Q2 | $2.72M | Buy |
115,788
+75,937
| +191% | +$1.62M | ﹤0.01% | 2467 |
|
|
2024
Q1 | $1.01M | Buy |
39,851
+11,400
| +40% | +$274K | ﹤0.01% | 2986 |
|
|
2023
Q4 | $664K | Sell |
28,451
-224,102
| -89% | -$4.42M | ﹤0.01% | 3078 |
|
|
2023
Q3 | $12.8M | Buy |
252,553
+16,104
| +7% | +$750K | ﹤0.01% | 1599 |
|
|
2023
Q2 | $11M | Buy |
236,449
+217,796
| +1,168% | +$9.98M | ﹤0.01% | 1750 |
|
|
2023
Q1 | $714K | Sell |
18,653
-184,375
| -91% | -$8.22M | ﹤0.01% | 3077 |
|
|
2022
Q4 | $11.1M | Sell |
203,028
-34,858
| -15% | -$1.49M | ﹤0.01% | 1775 |
|
|
2022
Q3 | $8.1M | Buy |
+237,886
| New | +$3.64M | ﹤0.01% | 1936 |
|
|
2022
Q2 | – | Sell |
-10,585
| Closed | -$150K | – | 4033 |
|
|
2022
Q1 | $150K | Buy |
10,585
+156
| +1% | +$2.73K | ﹤0.01% | 3819 |
|
|
2021
Q4 | $221K | Sell |
10,429
-1,227
| -11% | -$27.2K | ﹤0.01% | 3742 |
|
|
2021
Q3 | $260K | Buy |
11,656
+1,627
| +16% | +$36.8K | ﹤0.01% | 3693 |
|
|
2021
Q2 | $249K | Buy |
+10,029
| New | +$282K | ﹤0.01% | 3709 |
|
Other funds holding AKRO
Invesco's AKRO Position: Q4 2025 in Review
Invesco sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 63,542 shares — an estimated $3.02M sold.
Invesco first reported a position in AKRO in Q2 2021 and held it in 17 quarters. The position peaked at $12.8M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Invesco reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Invesco sold 63,542 Akero Therapeutics shares in Q4 2025, an estimated $3.02M.
- Invesco first reported a position in Akero Therapeutics in Q2 2021 and held it in 17 quarters.
- Invesco's Akero Therapeutics position peaked at $12.8M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Invesco's 13F filing for Q4 2025, filed 19 Feb 2026.